Review Article

Changing Epidemiology of Hepatocellular Adenoma in the United States: Review of the Literature

Table 1

Published series of hepatocellular adenoma in the United States (1985–2011).

Author
Year of publication
Study duration
Sample populationHormonal therapy (%)Women (%)Mean ageSingleMultiplePresenting symptomsHemorrhageMalignancyTreatment

Deodhar et al. [8]
2011
(2006-2007)
8Single-center series, bland embolization4/8 (50%)7/8 (87.5%)391 (12.5%)7 (87.5%)6 (75%) asymptomatic
1 (12.5%) rupture
1 (12.5%) abdominal pain
1/8 (12.5%)0Bland embolization (all)
Bunchorntavakul
et al. [9]
2011
(2005–2010)
60Single-center series45 (75%)58 (97%)36 (median)28%72%36 (60%) incidental
15 (25%) abdominal pain
7 (11.7%) bleeding
2 (3.3%) abnormal LFTs
7 (11.6%)017 resection
9 TAE
8 sequential TAE + resection
26 observation
Mounajjed and Wu [10]
2011
(1994–2010)
35Single-center series from pathology database 23/29 (79%)30 (86%)3915 (43%)20 (57%)NR10/49 (20%)0Resection (all)
Deneve et al. [11]
2009
(1997–2006)
124Multicenter surgical series 55%116 (94%)3977 (62%)47 (38%)NR31 (25%)5 (4%)119 resection
5 embolization
8 RFA (during resection)
Cho et al. [12]
2008
(1988–2007)
41Single-center surgical series22 (54%)38 (93%)36 (median)NRNR29 (70%) abdominal pain
7 (17%) incidental (on imaging)
3 (7%) abnormal LFTs
2 (5%) incidental (laparoscopy)
12 (29%)2 (4.8%)Resection (all)
Charny et al. [13]
2001
(1992–1999)
12Surgical seriesNR10 (83%)34NRNR8 (67%) “symptoms”
3 (25%) abnormal LFTs
NR1/88 resection
Reddy [14]
2001
(1983–1997)
25Single-center series, database of cases from radiologic or surgical diagnosis21/22 (95%)125 (100%)3316 (64%)9 (36%)3 (12%) rupture3 (12%)1 (4%)19 resection
1 unresectable
2 no intervention
Ault et al. [15]
1996
(1985–1995)
11Single-center surgical series9/11 (82%)10 (91%)37.68 (73%)3 (27%)10 (91%) abdominal pain 4 (36%)3 (27.2%)4 resection
4 observation
4 embolization
Nagorney [16]
1995
(1989–1993)
24Single-center series9/22 (41%)22 (92%)3620 (83%)4 (17%)19 (79%) symptomatic42219 resection
4 observation
1 liver transplantation

TAE: transarterial embolization, NR: not reported.
1No data on OCP use in 3.
2One HCC, one intrahepatic cholangiocarcinoma.